

RESULTS OF PHARMACOGENOMIC TEST

Your patient is a normal metabolizer of clopidogrel based on genotype.

Based on genetic testing ordered that included CYP2C19 variants involved in the metabolism of clopidogrel (Plavix), your patient had 2 functional alleles indicating normal metabolism and is expected to respond normally to clopidogrel.

Standard dosing of clopidogrel is recommended.

RESULTS OF PHARMACOGENOMIC TEST

Your patient is an intermediate metabolizer of clopidogrel based on genotype.

Based on genetic testing ordered that included CYP2C19 involved in the metabolism of clopidogrel (Plavix), your patient had 1 copy of a loss of function allele indicating this treating this patient with clopidogrel (Plavix) may lead to inadequate anti-platelet response. Intermediate metabolizers treated with clopidogrel at standard doses exhibit higher rates of stent thrombosis/other cardiovascular events.

Switching treatment from clopidogrel to another anti-platelet drug is recommended unless contraindicated. These drugs include either:

- Prasugrel (Effient) 60mg loading dose and then 10 mg daily
- Ticagrelor (Brilinta) 180mg loading dose and then 90 mg daily.

If neither drug is selected, clopidogrel may be continued at 75 mg daily.

Contraindications include:

- prasugrel -history of stroke or TIA, age >75 yo, or weight <60kg
- ticagrelor - history of intracranial bleed or severe hepatic impairment.

RESULTS OF PHARMACOGENOMIC TEST

Your patient is a poor metabolizer of clopidogrel based on genotype.

Based on genetic testing ordered that included CYP2C19 involved in the metabolism of clopidogrel (Plavix), your patient had 2 copies of a loss of function allele indicating that treating this patient with clopidogrel (Plavix) may lead to inadequate anti-platelet response. Poor metabolizers treated with clopidogrel at standard doses exhibit higher rates of stent thrombosis/other cardiovascular events.

Switching treatment from clopidogrel to another anti-platelet drug is recommended unless contraindicated. These drugs include either:

- Prasugrel (Effient) 60 mg loading dose and then 10 mg daily
- Ticagrelor (Brilinta) 180mg loading dose and then 90 mg daily.

If neither drug is selected, clopidogrel may be continued at 75 mg daily.

Contraindications to the alternative drugs include:

- prasugrel -history of stroke or TIA, age >75 yo, or weight <60kg
- ticagrelor - history of intracranial bleed or severe hepatic impairment.